Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
Identifieur interne : 000251 ( Main/Exploration ); précédent : 000250; suivant : 000252Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
Auteurs : Anna K. Lugnér [Pays-Bas] ; Michiel Van Boven ; Robin De Vries ; Maarten J. Postma ; Jacco WallingaSource :
- BMJ (Clinical research ed.) [ 1756-1833 ] ; 2012.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Allemagne (épidémiologie), Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Coûts des soins de santé, Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Grippe humaine (), Grippe humaine (transmission), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains, Jeune adulte, Modèles biologiques, Modèles économiques, Nourrisson, Nouveau-né, Pandémies (), Pandémies (économie), Pays-Bas (épidémiologie), Royaume-Uni (épidémiologie), Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccination (), Vaccination (économie), Vaccins antigrippaux (économie), Virus de la grippe A.
- MESH :
- économie : Grippe humaine, Pandémies, Vaccination, Vaccins antigrippaux.
- épidémiologie : Allemagne, Grippe humaine, Pays-Bas, Royaume-Uni.
- Adolescent, Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Coûts des soins de santé, Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Grippe humaine, Humains, Jeune adulte, Modèles biologiques, Modèles économiques, Nourrisson, Nouveau-né, Pandémies, Sujet âgé, Sujet âgé de 80 ans ou plus, Vaccination, Virus de la grippe A.
- Wicri :
- geographic : Allemagne, Pays-Bas, Royaume-Uni.
English descriptors
- KwdEn :
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Cost-Benefit Analysis, Germany (epidemiology), Health Care Costs, Humans, Infant, Infant, Newborn, Influenza A virus, Influenza Vaccines (economics), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Influenza, Human (transmission), Middle Aged, Models, Biological, Models, Economic, Netherlands (epidemiology), Pandemics (economics), Pandemics (prevention & control), Quality-Adjusted Life Years, United Kingdom (epidemiology), Vaccination (economics), Vaccination (methods), Young Adult.
- MESH :
- chemical , economics : Influenza Vaccines.
- geographic , epidemiology : Germany, Netherlands, United Kingdom.
- economics : Influenza, Human, Pandemics, Vaccination.
- epidemiology : Influenza, Human.
- methods : Vaccination.
- prevention & control : Influenza, Human, Pandemics.
- transmission : Influenza, Human.
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Cost-Benefit Analysis, Health Care Costs, Humans, Infant, Infant, Newborn, Influenza A virus, Middle Aged, Models, Biological, Models, Economic, Quality-Adjusted Life Years, Young Adult.
Abstract
OBJECTIVE
To investigate whether a single optimal vaccination strategy exists across countries to deal with a future influenza pandemic by comparing the cost effectiveness of different strategies in various pandemic scenarios for three European countries.
DESIGN
Economic and epidemic modelling study.
SETTINGS
General populations in Germany, the Netherlands, and the United Kingdom.
DATA SOURCES
Country specific patterns of social contact and demographic data.
MODEL
An age structured susceptible-exposed-infected-recovered transmission model that describes how an influenza A virus will spread in the populations of Germany, the Netherlands, and the United Kingdom.
INTERVENTIONS
Comparison of four vaccination strategies: no vaccination, blanket vaccination, vaccination of elderly people (≥ 65 years), and vaccination of high transmitters (5-19 years). The four strategies were evaluated for scenarios in which a vaccine became available early or at the peak of the pandemic, and in which either everyone was initially susceptible or older age groups had pre-existing immunity.
MAIN OUTCOME MEASURE
Cost per quality adjusted life years (QALYs) gained.
RESULTS
All vaccination strategies were cost effective (incremental cost per QALY gained, comparing intervention with non-intervention). In scenarios where the vaccine became available at the peak of the pandemic and there was pre-existing immunity among elderly people the incremental cost effectiveness ratios for vaccinating high transmitters were €7325 (£5815; $10,470) per QALY gained for Germany, €10,216 per QALY gained for the Netherlands, and €7280 per QALY gained for the United Kingdom. The most cost effective strategy not only differed across the pandemic scenarios but also between countries. Specifically, when the vaccine was available early in the pandemic and there was no pre-existing immunity, in Germany it would be most cost effective to vaccinate elderly people ( €940 per QALY gained), whereas it would be most cost effective to vaccinate high transmitters in both the Netherlands (€525 per QALY gained) and the United Kingdom (€163 per QALY gained). This difference in optimal strategies was due to differences in the demographic characteristics of the countries: Germany has a significantly higher proportion of elderly people compared with the Netherlands and the United Kingdom.
CONCLUSIONS
No single vaccination strategy was most cost effective across countries. With aging populations, pre-existing immunity in particular could be of crucial importance for the cost effectiveness of options to mitigate a future influenza pandemic.
DOI: 10.1136/bmj.e4445
PubMed: 22791791
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.</title><author><name sortKey="Lugner, Anna K" sort="Lugner, Anna K" uniqKey="Lugner A" first="Anna K" last="Lugnér">Anna K. Lugnér</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, Netherlands. anna.lugner@rivm.nl</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven</wicri:regionArea><wicri:noRegion>3720 BA Bilthoven</wicri:noRegion></affiliation></author><author><name sortKey="Van Boven, Michiel" sort="Van Boven, Michiel" uniqKey="Van Boven M" first="Michiel" last="Van Boven">Michiel Van Boven</name></author><author><name sortKey="De Vries, Robin" sort="De Vries, Robin" uniqKey="De Vries R" first="Robin" last="De Vries">Robin De Vries</name></author><author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J" last="Postma">Maarten J. Postma</name></author><author><name sortKey="Wallinga, Jacco" sort="Wallinga, Jacco" uniqKey="Wallinga J" first="Jacco" last="Wallinga">Jacco Wallinga</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22791791</idno><idno type="pmid">22791791</idno><idno type="doi">10.1136/bmj.e4445</idno><idno type="wicri:Area/Main/Corpus">000233</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000233</idno><idno type="wicri:Area/Main/Curation">000233</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000233</idno><idno type="wicri:Area/Main/Exploration">000233</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.</title><author><name sortKey="Lugner, Anna K" sort="Lugner, Anna K" uniqKey="Lugner A" first="Anna K" last="Lugnér">Anna K. Lugnér</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, Netherlands. anna.lugner@rivm.nl</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven</wicri:regionArea><wicri:noRegion>3720 BA Bilthoven</wicri:noRegion></affiliation></author><author><name sortKey="Van Boven, Michiel" sort="Van Boven, Michiel" uniqKey="Van Boven M" first="Michiel" last="Van Boven">Michiel Van Boven</name></author><author><name sortKey="De Vries, Robin" sort="De Vries, Robin" uniqKey="De Vries R" first="Robin" last="De Vries">Robin De Vries</name></author><author><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J" last="Postma">Maarten J. Postma</name></author><author><name sortKey="Wallinga, Jacco" sort="Wallinga, Jacco" uniqKey="Wallinga J" first="Jacco" last="Wallinga">Jacco Wallinga</name></author></analytic><series><title level="j">BMJ (Clinical research ed.)</title><idno type="eISSN">1756-1833</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Cost-Benefit Analysis</term><term>Germany (epidemiology)</term><term>Health Care Costs</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Influenza A virus</term><term>Influenza Vaccines (economics)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (transmission)</term><term>Middle Aged</term><term>Models, Biological</term><term>Models, Economic</term><term>Netherlands (epidemiology)</term><term>Pandemics (economics)</term><term>Pandemics (prevention & control)</term><term>Quality-Adjusted Life Years</term><term>United Kingdom (epidemiology)</term><term>Vaccination (economics)</term><term>Vaccination (methods)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Allemagne (épidémiologie)</term><term>Analyse coût-bénéfice</term><term>Années de vie ajustées sur la qualité</term><term>Coûts des soins de santé</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de l'âge</term><term>Grippe humaine ()</term><term>Grippe humaine (transmission)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Jeune adulte</term><term>Modèles biologiques</term><term>Modèles économiques</term><term>Nourrisson</term><term>Nouveau-né</term><term>Pandémies ()</term><term>Pandémies (économie)</term><term>Pays-Bas (épidémiologie)</term><term>Royaume-Uni (épidémiologie)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Vaccination ()</term><term>Vaccination (économie)</term><term>Vaccins antigrippaux (économie)</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term><term>Netherlands</term><term>United Kingdom</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term><term>Pandémies</term><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term><term>Pays-Bas</term><term>Royaume-Uni</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Cost-Benefit Analysis</term><term>Health Care Costs</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Influenza A virus</term><term>Middle Aged</term><term>Models, Biological</term><term>Models, Economic</term><term>Quality-Adjusted Life Years</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Années de vie ajustées sur la qualité</term><term>Coûts des soins de santé</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de l'âge</term><term>Grippe humaine</term><term>Humains</term><term>Jeune adulte</term><term>Modèles biologiques</term><term>Modèles économiques</term><term>Nourrisson</term><term>Nouveau-né</term><term>Pandémies</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Vaccination</term><term>Virus de la grippe A</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term><term>Pays-Bas</term><term>Royaume-Uni</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To investigate whether a single optimal vaccination strategy exists across countries to deal with a future influenza pandemic by comparing the cost effectiveness of different strategies in various pandemic scenarios for three European countries.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN</b></p><p>Economic and epidemic modelling study.</p></div><div type="abstract" xml:lang="en"><p><b>SETTINGS</b></p><p>General populations in Germany, the Netherlands, and the United Kingdom.</p></div><div type="abstract" xml:lang="en"><p><b>DATA SOURCES</b></p><p>Country specific patterns of social contact and demographic data.</p></div><div type="abstract" xml:lang="en"><p><b>MODEL</b></p><p>An age structured susceptible-exposed-infected-recovered transmission model that describes how an influenza A virus will spread in the populations of Germany, the Netherlands, and the United Kingdom.</p></div><div type="abstract" xml:lang="en"><p><b>INTERVENTIONS</b></p><p>Comparison of four vaccination strategies: no vaccination, blanket vaccination, vaccination of elderly people (≥ 65 years), and vaccination of high transmitters (5-19 years). The four strategies were evaluated for scenarios in which a vaccine became available early or at the peak of the pandemic, and in which either everyone was initially susceptible or older age groups had pre-existing immunity.</p></div><div type="abstract" xml:lang="en"><p><b>MAIN OUTCOME MEASURE</b></p><p>Cost per quality adjusted life years (QALYs) gained.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>All vaccination strategies were cost effective (incremental cost per QALY gained, comparing intervention with non-intervention). In scenarios where the vaccine became available at the peak of the pandemic and there was pre-existing immunity among elderly people the incremental cost effectiveness ratios for vaccinating high transmitters were €7325 (£5815; $10,470) per QALY gained for Germany, €10,216 per QALY gained for the Netherlands, and €7280 per QALY gained for the United Kingdom. The most cost effective strategy not only differed across the pandemic scenarios but also between countries. Specifically, when the vaccine was available early in the pandemic and there was no pre-existing immunity, in Germany it would be most cost effective to vaccinate elderly people ( €940 per QALY gained), whereas it would be most cost effective to vaccinate high transmitters in both the Netherlands (€525 per QALY gained) and the United Kingdom (€163 per QALY gained). This difference in optimal strategies was due to differences in the demographic characteristics of the countries: Germany has a significantly higher proportion of elderly people compared with the Netherlands and the United Kingdom.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>No single vaccination strategy was most cost effective across countries. With aging populations, pre-existing immunity in particular could be of crucial importance for the cost effectiveness of options to mitigate a future influenza pandemic.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22791791</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>345</Volume><PubDate><Year>2012</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.</ArticleTitle><Pagination><MedlinePgn>e4445</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.e4445</ELocationID><ELocationID EIdType="pii" ValidYN="Y">bmj.e4445</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate whether a single optimal vaccination strategy exists across countries to deal with a future influenza pandemic by comparing the cost effectiveness of different strategies in various pandemic scenarios for three European countries.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Economic and epidemic modelling study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">General populations in Germany, the Netherlands, and the United Kingdom.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Country specific patterns of social contact and demographic data.</AbstractText><AbstractText Label="MODEL" NlmCategory="METHODS">An age structured susceptible-exposed-infected-recovered transmission model that describes how an influenza A virus will spread in the populations of Germany, the Netherlands, and the United Kingdom.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Comparison of four vaccination strategies: no vaccination, blanket vaccination, vaccination of elderly people (≥ 65 years), and vaccination of high transmitters (5-19 years). The four strategies were evaluated for scenarios in which a vaccine became available early or at the peak of the pandemic, and in which either everyone was initially susceptible or older age groups had pre-existing immunity.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Cost per quality adjusted life years (QALYs) gained.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All vaccination strategies were cost effective (incremental cost per QALY gained, comparing intervention with non-intervention). In scenarios where the vaccine became available at the peak of the pandemic and there was pre-existing immunity among elderly people the incremental cost effectiveness ratios for vaccinating high transmitters were €7325 (£5815; $10,470) per QALY gained for Germany, €10,216 per QALY gained for the Netherlands, and €7280 per QALY gained for the United Kingdom. The most cost effective strategy not only differed across the pandemic scenarios but also between countries. Specifically, when the vaccine was available early in the pandemic and there was no pre-existing immunity, in Germany it would be most cost effective to vaccinate elderly people ( €940 per QALY gained), whereas it would be most cost effective to vaccinate high transmitters in both the Netherlands (€525 per QALY gained) and the United Kingdom (€163 per QALY gained). This difference in optimal strategies was due to differences in the demographic characteristics of the countries: Germany has a significantly higher proportion of elderly people compared with the Netherlands and the United Kingdom.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">No single vaccination strategy was most cost effective across countries. With aging populations, pre-existing immunity in particular could be of crucial importance for the cost effectiveness of options to mitigate a future influenza pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lugnér</LastName><ForeName>Anna K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, National Institute for Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, Netherlands. anna.lugner@rivm.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Boven</LastName><ForeName>Michiel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>de Vries</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Postma</LastName><ForeName>Maarten J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Wallinga</LastName><ForeName>Jacco</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="Y">Influenza A virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="Y">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="Y">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22791791</ArticleId><ArticleId IdType="pmc">PMC3395306</ArticleId><ArticleId IdType="doi">10.1136/bmj.e4445</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Euro Surveill. 2009 Jul 09;14(27):</Citation><ArticleIdList><ArticleId IdType="pubmed">19589332</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2006;24(4):373-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16605283</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2009 Oct;12(7):A221-481</Citation><ArticleIdList><ArticleId IdType="pubmed">19796258</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 1999 Sep-Oct;5(5):659-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10511522</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(7):e22308</Citation><ArticleIdList><ArticleId IdType="pubmed">21829456</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 1999;16 Suppl 1:33-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10623374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1958 Apr 19;1(7025):810-4</Citation><ArticleIdList><ArticleId IdType="pubmed">13526279</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2009 Mar-Apr;12(2):226-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18671770</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2007 Mar-Apr;10(2):98-116</Citation><ArticleIdList><ArticleId IdType="pubmed">17391419</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Nov 16;23(46-47):5365-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16029916</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Sep 25;325(5948):1705-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19696313</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Jul 27;442(7101):448-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16642006</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2006 Nov 15;164(10):936-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16968863</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Infect. 1998 Aug;121(1):129-38</Citation><ArticleIdList><ArticleId IdType="pubmed">9747764</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Biol Sci. 2007 Feb 22;274(1609):599-604</Citation><ArticleIdList><ArticleId IdType="pubmed">17476782</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(3):e33723</Citation><ArticleIdList><ArticleId IdType="pubmed">22470463</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2000 Aug;90(8):1241-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10937004</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Mar 11;28(12):2370-84</Citation><ArticleIdList><ArticleId IdType="pubmed">20096762</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(3):e33536</Citation><ArticleIdList><ArticleId IdType="pubmed">22470453</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2004 Apr 1;159(7):623-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15033640</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Aug 31;28(38):6210-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20643091</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Econ. 2010 May;19(5):518-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19382106</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Aug 12;309(5737):1083-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16079251</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1995 Oct 1;123(7):518-27</Citation><ArticleIdList><ArticleId IdType="pubmed">7661497</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5935-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16585506</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Sep 8;437(7056):209-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16079797</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2011 Sep;5(5):306-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21668690</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hyg. 1958 Sep;68(2):190-212</Citation><ArticleIdList><ArticleId IdType="pubmed">13571232</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2003 May;9(5):531-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12737735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ned Tijdschr Geneeskd. 1998 Sep 19;142(38):2075-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9856218</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Econ. 1995 Jun;14(2):171-89</Citation><ArticleIdList><ArticleId IdType="pubmed">10154656</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 1993 Apr;22(2):334-40</Citation><ArticleIdList><ArticleId IdType="pubmed">8505193</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Curr. 2009 Aug 26;1:RRN1013</Citation><ArticleIdList><ArticleId IdType="pubmed">20029607</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Jul 4;26(29-30):3742-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18524428</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):923-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20080777</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2010 Sep-Oct;13(6):853-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21054659</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2008 Mar 25;5(3):e74</Citation><ArticleIdList><ArticleId IdType="pubmed">18366252</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country></list><tree><noCountry><name sortKey="De Vries, Robin" sort="De Vries, Robin" uniqKey="De Vries R" first="Robin" last="De Vries">Robin De Vries</name><name sortKey="Postma, Maarten J" sort="Postma, Maarten J" uniqKey="Postma M" first="Maarten J" last="Postma">Maarten J. Postma</name><name sortKey="Van Boven, Michiel" sort="Van Boven, Michiel" uniqKey="Van Boven M" first="Michiel" last="Van Boven">Michiel Van Boven</name><name sortKey="Wallinga, Jacco" sort="Wallinga, Jacco" uniqKey="Wallinga J" first="Jacco" last="Wallinga">Jacco Wallinga</name></noCountry><country name="Pays-Bas"><noRegion><name sortKey="Lugner, Anna K" sort="Lugner, Anna K" uniqKey="Lugner A" first="Anna K" last="Lugnér">Anna K. Lugnér</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000251 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000251 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22791791
|texte= Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22791791" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |